AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences

Co-Founder and CEO Wyatt McDonnell describes why Infinimmune believes that learning directly from the human adaptive immune system is an ideal way to engineer antibodies, and he describes why he believes the model will be successful for drug development both inside and outside of autoimmune conditions.